FULL DISCLOSURE: This is sponsored content for DiagnaMed Holdings.
DiagnaMed Holdings (CSE: DMED) is reporting this morning that its flagship Brain Age Brain Health AI Platform has obtained the status of being clinically validated, following the publishing of a peer-reviewed paper.
The paper, published in Frontiers in Neuroergonomics, is titled, “Brain-age estimation with a low-cost EEG-headset: effectiveness and implications for large-scale screening and brain optimization.” The paper, published April 24, was led by Dr John Kounios, whom works at the Department of Psychological and Brain Sciences of Drexel University in Philadelphia, as well as by Dr Jessica Fleck of the Department of Psychology at Stockton University in New Jersey.
The researchers of Drexel University, along with Stockton University, are responsible for the development of the artificial intelligence technique used by Brain Age that can effectively estimate an individual’s brain age based on electroencephalogram brain scans. The scan is conducted using a headset, with machine learning then using the data collected to estimate on an individuals brain age.
The resulting data can then be used as a screening tool to identify the possibility of underlying age-related pathology, which can then be further followed up with additional diagnostics. DiagnaMed expects that it can assist in beginning the screening process earlier in life for brain decline, rather than waiting until symptoms develop later in life, enabling earlier treatment of age-related neurological disorders.
The company, which earlier this week announced it is beginning its Canada-wide rollout of the Brain Age platform to clinics across Canada, believes the initial target market for the platform could be “at least 50 million [people] in the U.S. alone.”
“The validation of BRAIN AGE® in a peer-reviewed paper is a significant milestone for us that culminates nearly two years of research and now unlocks the potential of BRAIN AGE® for the millions of people seeking to improve their overall brain health. We are now positioned to execute our commercialization plan by educating medical communities about the potential of BRAIN AGE® and its value proposition to a network of healthcare clinics as a service to their clients,” commented CEO Fabio Chianelli.
DiangaMed Holdings last traded at $0.035 on the CSE.
FULL DISCLOSURE: DiagnaMed Holdings is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of DiagnaMed Holdings. The author has been compensated to cover DiagnaMed Holdings on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
